Truace
Subscribe

Artificial intelligence in cancer transcriptomics: methods, applications in oncology, and limitations

Background. Transcriptomic data show which genes are active in cells and tissues. Machine-learning and deep-learning methods use these data to classify samples, integrate different datasets, and predict biological properties and treatment response. In oncology, a major challenge is transferring patterns identified in experimental models to tumor samples from patients. Objective. To critically synthesize current artificial-intelligence methods for transcriptomic analysis, with emphasis on oncology applications, t…

By the Truvace desk2 min read1 sourcePeer-reviewedTRV-2026-1711· cite & verify
Artificial intelligence in cancer transcriptomics: methods, applications in oncology, and limitations
"McArdle Laboratory for Cancer Research" by wackybadger is licensed under CC BY-SA 2.0. To view a copy of this license, visit https://creativecommons.org/licenses/by-sa/2.0/.

In brief

A critical narrative review covering primary studies and methodological papers, with the literature updated through August 13, 2026, assessed how machine-learning and deep-learning methods are applied to transcriptomic data in cancer. It identified single-cell analysis, spatially resolved tumor diagnostics, and drug-response prediction as the most developed uses.

The review matters because translating patterns found in experimental models to real patient tumors is a central difficulty in oncology. Independent comparisons suggest that simply scaling up models does not guarantee better results. What remains uncertain is how well specific tools hold up in independent patient cohorts.

Main points

  1. Transcriptomic data show which genes are active in cells and tissues and feed AI classification, dataset integration, and treatment-response prediction.
  2. The most developed areas are single-cell data analysis, spatially resolved tumor diagnostics, and drug-response prediction.
  3. Independent comparative evaluations found that larger, more complex models do not necessarily outperform simpler methods.
  4. Clinical translation requires accounting for cellular composition, batch differences, mismatched response measures, information leakage, and external validation.

The problem

Larger, more complex models are not guaranteed to outperform simpler methods, and moving models from experimental systems to patient tumors requires careful handling of batch effects, information leakage, and external validation.

The rundown

The review is a critical narrative synthesis of primary studies and methodological papers, supplemented by a description of the authors' own publication sample for 2021 to 2026. Its stated aim was to cover methods, oncology applications, model transfer to patient data, and validation requirements.

A key obstacle is carrying patterns learned in experimental models over to tumor samples from patients. The authors say this requires aligning experimental and clinical response measures and guarding against technical differences between measurement batches.

The authors conclude that AI should be treated as a data-analysis tool rather than a replacement for experimental or clinical validation. Its value depends on data quality, correct task definition, and sustained performance in independent cohorts.

Sources

  1. Peer-reviewedPharmacokinetics and Pharmacodynamics2026-10-16

The debate